• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

严重免疫介导的药物性肝损伤与伊班膦酸盐相关：病例报告。

Severe immune-mediated drug-induced liver injury linked to ibandronate: a case report.

机构信息

Division of Gastroenterology and Hepatology, Geneva University Hospital, Geneva, Switzerland.

出版信息

J Hepatol. 2013 Nov;59(5):1139-42. doi: 10.1016/j.jhep.2013.06.003. Epub 2013 Jun 14.

DOI:10.1016/j.jhep.2013.06.003
PMID:23770145
Abstract

Ibandronate is a widely used bisphosphonate with no previously well documented hepatotoxicity. We report the first case of ibandronate-related hepatotoxicity and, to our knowledge, the first case of immune-mediated drug-induced liver injury (DILI) related to bisphosphonates.

摘要

伊班膦酸盐是一种广泛使用的双膦酸盐，以前没有明确记录的肝毒性。我们报告了首例伊班膦酸盐相关肝毒性病例，据我们所知，也是首例与双膦酸盐相关的免疫介导的药物性肝损伤（DILI）病例。

相似文献

1
Severe immune-mediated drug-induced liver injury linked to ibandronate: a case report.严重免疫介导的药物性肝损伤与伊班膦酸盐相关：病例报告。
J Hepatol. 2013 Nov;59(5):1139-42. doi: 10.1016/j.jhep.2013.06.003. Epub 2013 Jun 14.
2
Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Published 2020/2021 Based on RUCAM as Causality Assessment Method.COVID-19 患者药物性肝损伤：基于 RUCAM 因果关系评估方法，对 2020/2021 年发表的 996 例 DILI 病例的系统评价。
Int J Mol Sci. 2022 Apr 27;23(9):4828. doi: 10.3390/ijms23094828.
3
Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis.早期 ALT 对皮质类固醇治疗的反应可将特发性药物性肝损伤与自身免疫性肝炎区分开来。
Liver Int. 2019 Oct;39(10):1906-1917. doi: 10.1111/liv.14195. Epub 2019 Aug 5.
4
Relapse and Need for Extended Immunosuppression: Novel Features of Drug-Induced Autoimmune Hepatitis.药物性自身免疫性肝炎的新特征：复发和需要延长免疫抑制治疗。
Digestion. 2023;104(3):243-248. doi: 10.1159/000528329. Epub 2023 Jan 5.
5
Liver Injury in People With HIV on Antituberculosis and/or Antiretroviral Therapy-Assessing Causality Using the Updated Roussel Uclaf Causality Assessment Method.抗结核和/或抗反转录病毒治疗的 HIV 感染者中的肝损伤：使用更新的 Roussel Uclaf 因果关系评估方法评估因果关系。
Pharmacoepidemiol Drug Saf. 2024 Oct;33(10):e5883. doi: 10.1002/pds.5883.
6
Clinical characteristics and outcomes of traditional Chinese medicine-induced liver injury: a systematic review.中药肝损伤的临床特征和转归：一项系统评价。
Expert Rev Gastroenterol Hepatol. 2018 Apr;12(4):425-434. doi: 10.1080/17474124.2018.1427581. Epub 2018 Jan 18.
7
Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.应用 Hy's 法则和一种新的复合算法预测药物性肝损伤患者的急性肝衰竭。
Gastroenterology. 2014 Jul;147(1):109-118.e5. doi: 10.1053/j.gastro.2014.03.050. Epub 2014 Apr 1.
8
Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method.经 Roussel Uclaf 因果关系评估方法评估的 3312 例药物性肝损伤病例中的排名前位药物。
Expert Opin Drug Metab Toxicol. 2018 Nov;14(11):1169-1187. doi: 10.1080/17425255.2018.1539077. Epub 2018 Oct 29.
9
Drug-Induced Liver Injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) Still Used 25 Years After Its Launch?药物性肝损伤：为何在其问世 25 年后 Roussel Uclaf 因果关系评估方法（RUCAM）仍在使用？
Drug Saf. 2018 Aug;41(8):735-743. doi: 10.1007/s40264-018-0654-2.
10
A detection algorithm for drug-induced liver injury in medical information databases using the Japanese diagnostic scale and its comparison with the Council for International Organizations of Medical Sciences/the Roussel Uclaf Causality Assessment Method scale.一种利用日本诊断量表在医学信息数据库中检测药物性肝损伤的算法及其与国际医学科学组织理事会/鲁塞尔·优克福因果关系评估方法量表的比较
Pharmacoepidemiol Drug Saf. 2014 Sep;23(9):984-8. doi: 10.1002/pds.3603. Epub 2014 Mar 5.

引用本文的文献

1
Role of Ursodeoxycholic Acid in Treating and Preventing Idiosyncratic Drug-Induced Liver Injury. A Systematic Review.熊去氧胆酸在治疗和预防特异质性药物性肝损伤中的作用。一项系统评价。
Front Pharmacol. 2021 Oct 27;12:744488. doi: 10.3389/fphar.2021.744488. eCollection 2021.
2
Therapeutic Dimensions of Bisphosphonates: A Clinical Update.双膦酸盐的治疗维度：临床最新进展
Int J Prev Med. 2020 Oct 5;11:166. doi: 10.4103/ijpvm.IJPVM_33_19. eCollection 2020.
3
Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993-Mid 2020: A Comprehensive Analysis.
1993年至2020年年中发表的81856例特异质性药物性肝损伤和14029例药物超敏反应性肝损伤病例中RUCAM在因果关系评估中的全球应用：一项综合分析
Medicines (Basel). 2020 Sep 29;7(10):62. doi: 10.3390/medicines7100062.
4
RUCAM in Drug and Herb Induced Liver Injury: The Update.药物及草药所致肝损伤的RUCAM：最新进展
Int J Mol Sci. 2015 Dec 24;17(1):14. doi: 10.3390/ijms17010014.
5
Zoledronic acid-induced hepatotoxicity relieved after subsequent infusions in a Chinese woman with glucocorticoid-induced osteoporosis.一名患有糖皮质激素诱导性骨质疏松症的中国女性在后续输注后，唑来膦酸诱导的肝毒性得到缓解。
Eur J Med Res. 2015 Aug 22;20(1):68. doi: 10.1186/s40001-015-0161-1.